[ad_1] The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine …
Read More »FDA Approves Lorlatinib for ALK-positive Non-Small Cell Lung Cancer
